NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Unprecedented smoking cessation levels seen in alpha-1 patients

By Mindo - 18th Nov 2019

A new Irish study has found that a diagnosis of alpha-1 antitrypsin deficiency (AATD), regardless of severity, leads to long-term smoking cessation, with higher quit levels seen than among patients with lung cancer or chronic obstructive pulmonary disease (COPD).

The new research, conducted with the help of participants in the National AATD Registry at Beaumont Hospital, Dublin, found that just 2 per cent of smokers with the most severe type of AATD continued smoking after diagnosis, while 16 per cent of those with less severe types of the deficiency continued to smoke.

These figures contrast starkly with quit levels among smokers diagnosed with lung cancer or COPD, where large numbers of patients continue smoking, research shows.

The study findings coincide with updated figures from the national-targeted AATD screening programme, which began 15 years ago, and provide new insights into Ireland’s AATD population. Ireland has one of the highest rates in the world of AATD, a rare genetic disorder which can lead to COPD, liver disease, and premature death.

Dr Alessandro Franciosi, Clinical Lecturer at the RCSI — who carried out the research with Dr Tomás Carroll, Chief Scientist at the Alpha-1 Foundation Ireland and Senior Lecturer at the RCSI — told the Medical Independent that testing for AATD should be much more widespread in Ireland to prevent disease and should be offered to all patients diagnosed with COPD, as per World Health Organisation  guidelines.

With this mild form of the disorder, people are only at-risk of lung disease if they smoke.

According to Dr Carroll, the HSE’s national smoking cessation programme, which he describes as one of the best in the world, could be used to communicate this message to smokers, helping to prevent or postpone lung disease in high-risk smokers with AATD.

The research was presented at the recent Alpha-1 Foundation Conference in Dublin.

Leave a Reply

Latest Issue
medical independent 21st November
The Medical Independent 21st November 2023

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read